Key facts
- It has raised $27.8M; the latest was Later Stage VC ($13.8M) in May 2025.
- Notable investors include Yonghua Capital, Guangdong Technology Financial Group, Tailong VC, Infinity Group, Hankang Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for CureGene Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for CureGene Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CureGene Pharmaceutical
Developer and provider of drugs designed to treat cardiovascular and cerebrovascular diseases. The company focuses on the research and development of innovative drugs in the fields of cardiovascular and cerebrovascular diseases and antiviral diseases. It is currently promoting the clinical development of two dosage forms, intravenous injection and oral tablets, for various indications such as acute coronary syndrome, myocardial infarction, and stroke.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Website
- curegene.com.cn/
- Ownership
- Privately Held (backing)
CureGene Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CureGene Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CureGene Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.